Pharmaceutical company Johnson & Johnson has agreed to pay $230 million to New York State, ahead of a trial pertaining to the opioid crisis set to begin on Tuesday, the Wall Street Journal reported.
The deal will keep Johnson & Johnson out of the trial in New York, which includes other makers of opioid prescription drugs, but will not remove the company from trials scheduled in other states. Most U.S. states and over 3,000 counties, cities, and local governments have filed suit against drug makers in the wake of the crisis, including AmerisourceBergen, Cardinal Health Inc., and McKessen Corp.
Comments
Post a Comment